Targeted therapies aimed at inhibiting NF-κB signaling have been explored as a means to overcome drug resistance and improve treatment outcomes in cancers such as lymphoma, multiple myeloma, and breast cancer [69,70]. Here, NFKB1 is linked to plasma cell myeloma.